

FOR THE EXCLUSIVE USE OF LDEPAOLO@PICKETT-SPROUSE.COM

From the Triangle Business Journal:

<https://www.bizjournals.com/triangle/news/2018/01/03/biogen-completes-eisai-deal-with-15-6m-building.html>

## Biogen completes Eisai deal with \$15.6M RTP building buy

Jan 3, 2018, 8:36am EST Updated: Jan 3, 2018, 8:50am EST

Biogen (Nasdaq: BILB) has completed a prior deal with Eisai through a \$15.6 million building purchase.

According to Durham County deed records, Cambridge, Massachusetts-based Biogen bought the building at 900 Davis Drive from Eisai just last month. But the transaction is “the natural conclusion” of a deal reached with Eisai about two-and-a-half years ago, a Biogen spokesman said in an email.

In July 2015, Eisai announced an agreement to transfer ownership of its 275,000-square-foot, 124-acre manufacturing campus in Research Triangle Park to Biogen. The agreement, Eisai stated at the time, “expands upon the capacity-sharing manufacturing alliance Eisai and Biogen have had in place at the RTP facility since early 2013.”



TBJ FILE PHOTO  
Biogen, RTP, N.C.

“Biogen will continue to manufacture oral solid-dose products for Eisai. In addition, Eisai has entered into a new manufacturing agreement whereby Biogen will manufacture Eisai's parenteral products [drugs administered by injection],” Eisai